CHIARADONNA, FERDINANDO
 Distribuzione geografica
Continente #
NA - Nord America 8.703
EU - Europa 7.608
AS - Asia 4.840
SA - Sud America 691
AF - Africa 136
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 7
Totale 22.001
Nazione #
US - Stati Uniti d'America 8.277
SE - Svezia 2.202
IT - Italia 1.735
SG - Singapore 1.696
CN - Cina 1.188
DE - Germania 1.050
RU - Federazione Russa 682
VN - Vietnam 564
HK - Hong Kong 522
BR - Brasile 519
CA - Canada 352
PL - Polonia 345
IE - Irlanda 283
GB - Regno Unito 271
FR - Francia 263
IN - India 172
UA - Ucraina 171
FI - Finlandia 150
NL - Olanda 108
KR - Corea 92
TR - Turchia 92
BD - Bangladesh 91
ID - Indonesia 82
AT - Austria 74
AR - Argentina 68
DK - Danimarca 65
IQ - Iraq 51
JP - Giappone 51
ES - Italia 49
ZA - Sudafrica 49
MX - Messico 46
CH - Svizzera 34
BE - Belgio 32
SA - Arabia Saudita 27
PK - Pakistan 25
PH - Filippine 24
EC - Ecuador 23
IR - Iran 21
UZ - Uzbekistan 21
CO - Colombia 19
MA - Marocco 19
CZ - Repubblica Ceca 16
PT - Portogallo 15
VE - Venezuela 15
JO - Giordania 14
CL - Cile 13
PY - Paraguay 13
TN - Tunisia 13
AU - Australia 12
EG - Egitto 12
TW - Taiwan 12
NP - Nepal 10
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
MY - Malesia 9
PE - Perù 9
UY - Uruguay 9
AZ - Azerbaigian 8
LT - Lituania 8
LU - Lussemburgo 8
AL - Albania 7
KE - Kenya 7
KG - Kirghizistan 7
PS - Palestinian Territory 7
ET - Etiopia 6
GR - Grecia 6
HU - Ungheria 6
JM - Giamaica 6
LB - Libano 6
OM - Oman 6
RO - Romania 6
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
CR - Costa Rica 4
KZ - Kazakistan 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
BO - Bolivia 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
EU - Europa 3
IL - Israele 3
MN - Mongolia 3
NI - Nicaragua 3
SI - Slovenia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
BY - Bielorussia 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
HR - Croazia 2
KH - Cambogia 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
QA - Qatar 2
Totale 21.977
Città #
Stockholm 1.882
Ann Arbor 1.229
Singapore 1.017
Ashburn 809
Frankfurt am Main 696
San Jose 618
Milan 514
Woodbridge 501
Hong Kong 491
Fairfield 404
Wilmington 342
Chandler 337
Houston 292
Kraków 280
Dublin 275
Dallas 243
New York 217
Toronto 208
Beijing 201
Los Angeles 191
Jacksonville 168
Dearborn 167
Seattle 162
Ho Chi Minh City 160
Hefei 159
Santa Clara 158
Cambridge 146
Munich 132
Chicago 123
The Dalles 121
Hanoi 118
Council Bluffs 93
Seoul 87
Princeton 84
Buffalo 82
Helsinki 77
Lauterbourg 70
Boardman 66
Jakarta 66
Nanjing 62
Shanghai 61
São Paulo 60
Moscow 52
Vienna 51
North Kansas City 50
Rome 50
Dong Ket 49
Guangzhou 45
Warsaw 44
Lawrence 42
Montréal 38
San Diego 38
Tokyo 35
Montreal 34
Orem 34
Altamura 32
Cento 32
Chennai 31
Johannesburg 31
Atlanta 30
Denver 30
Brussels 29
Nuremberg 29
Da Nang 28
Lachine 28
Bologna 27
Turin 27
Baghdad 25
London 25
Nanchang 25
Brooklyn 23
Naples 22
Poplar 22
Tianjin 21
Amsterdam 20
Torino 20
Ankara 19
Zhengzhou 19
Zurich 19
Andover 18
Falls Church 18
Paris 18
Hyderabad 17
Manchester 17
Rio de Janeiro 17
Salt Lake City 17
Tashkent 17
Kent 16
Boston 14
Brusuglio 14
Dhaka 14
Kunming 14
San Francisco 14
Amman 13
Hebei 13
Huizen 13
Lappeenranta 13
Mumbai 13
Phoenix 13
Piscataway 13
Totale 14.661
Nome #
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis 2.752
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 707
Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis 684
Fuzzy modeling and global optimization to predict novel therapeutic targets in cancer cells 536
Design, Synthesis, and Preliminary Biological Evaluation of GlcNAc-6P Analogues for the Modulation of Phosphoacetylglucosamine Mutase 1 (AGM1/PGM3) 495
Protein Kinase A Activation Promotes Cancer Cell Resistance to Glucose Starvation and Anoikis 468
The Nutrient-Sensing Hexosamine Biosynthetic Pathway as the Hub of Cancer Metabolic Rewiring. 464
Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation 456
Central metabolism of functionally heterogeneous mesenchymal stromal cells 406
From cancer metabolism to new biomarkers and drug targets 400
Mitochondria in Focus: Targeting the Cell-Death Mechanism 390
Analysis of mitochondrial metabolism in situ: Combining stable isotope labeling with selective permeabilization 390
RAS and PKA pathways in cancer: new insight from transcriptional analysis 367
Transcriptional profiling of immortalized and K-ras-transformed mouse fibroblasts upon PKA stimulation by forskolin in low glucose availability 366
Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth 365
Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling 338
Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor 338
Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts 332
The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells 332
Ras-dependent carbon metabolism and transformation in mouse fibroblasts 323
Metabolic reprogramming and dysregulated metabolism: Cause, consequence and/or enabler of environmental carcinogenesis? 321
Data recovery and integration from public databases uncovers transformation-specific transcriptional downregulation of cAMP-PKA pathway-encoding genes 316
Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS 309
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: The challenge ahead 308
Integrative transcriptional analysis between human and mouse cancer cells provides a common set of transformation associated genes 296
Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response 296
New Insights into the Connection between Histone Deacetylases, Cell Metabolism, and Cancer 295
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies 286
Glutamine deprivation induces abortive S-phase rescued by deoxyribonucleotides in K-ras transformed fibroblasts 283
Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration 281
Multi-pathway blood biomarkers to target and monitor multidimensional prevention of cognitive and functional decline (nested in the IN-TeMPO study framed within the world-wide FINGERS network) 278
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy 278
Acquired glucose sensitivity of k-ras transformed fibroblasts 278
Cancer Metabolism as a New Real Target in Tumor Therapy 276
Genetic and Molecular Characterization of The Human Osteosarcoma 3AB-OS Cancer Stem Cell Line: A Possible Model For Studying Osteosarcoma Origin and Stemness 273
Systems biology and the molecular circuits of cancer 271
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer 264
Chiral trimethyl lock based on vicinal disubstituent effect: prolonged release of Camptothecin into cancer cells 263
PGM3 inhibition Shows cooperative Effects With Erastin inducing Pancreatic cancer cell death via activation of the Unfolded Protein Response 263
Mitochondrial Complex I inhibitors and forced oxidative phosphorylation synergize in inducing cancer cell death 263
Towards a systems biology approach to mammalian cell cycle: modeling the entrance into S phase of quiescent fibroblasts after serum stimulation 262
Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells 258
PKA stimulation protects K-ras transformed cells from apoptosis induced by glucose depletion reactivating mitochondrial function 256
PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer 256
Vitamin D supplementation and cancer mortality: Narrative review of observational studies and clinical trials 240
Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth 238
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis 227
Hexosamine Pathway inhibition: one molecule able to induce a Brcaness phenotype as promising cancer therapy 217
PGM3 inhibition shows cooperative effects with Erastin inducing pancreatic cancer cell death via activation of the Unfolded Protein Response 217
Glucose shortage dependent apoptosis in transformed cells upon activation of UPR-autophagy pathway 208
Itaconate controls its own synthesis via feedback-inhibition of reverse TCA cycle activity at IDH2 203
PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect 198
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy 193
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis 189
Moving beyond the Tip of the Iceberg: DJ-1 Implications in Cancer Metabolism 180
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy 173
VITAMIN D SUPPLEMENTATION MAY IMPROVE COVID-19 PROGNOSIS? EVIDENCE FROM A SYSTEMATIC REVIEW AND META-ANALYSIS 172
PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells 167
PO-259 Inhibition of the hexosamine biosynthetic pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis 164
Multicomponent interventions and technologies to reduce the burden of frailty, functional, and cognitive decline: insights from the Age-It Research Program 156
Inhibition of the Hexosamine Biosynthetic Pathway Enhances Enzalutamide Response in Prostate Cancer Cells 148
Hexosamine Biosynthetic Pathway inhibition sensitizes pancreatic cancer cells to DNA damage 142
Comparative transcriptional analysis between a K-ras cell model of transformation and the NCI60 human cancer cells collection 141
Targeting the Hexosamine Biosynthetic Pathway with a novel PGM3 inhibitor, FR054, to suppress tumour growth and enhance chemotherapy sensitivity in cancer 136
PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells 132
Hexosamine Biosynthetic Pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage 116
High throughput metabolomics analysis in normal and K-Ras transformed murine fibroblasts 113
PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect 101
Exploiting DNA damage response protein O-glycosylation to enhance chemotherapy in pancreatic cancer. 95
Exploiting DNA damage protein O-glycosylation to enhance chemotherapy in pancreatic cancer 94
Targeting Hexosamine Biosynthetic Pathway to Overcome Resistance in Pancreatic Cancer Treatment 90
Targeting Hexosamine Biosynthetic Pathway to Overcome Resistance in Pancreatic Cancer Treatment 89
Inhibition of HBP by targeting PGM3 enzyme as new anticancer therapy 87
PGM3 inhibition shows cooperative effects with erastin inducing pancreatic cancer cell death via activation of the unfolded protein response 82
PGM3 inhibition shows cooperative effects with erastin inducing pancreatic cancer cell death via activation of the unfolded protein response 75
Hexosamine biosynthetic pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage 73
Histone glycation: a novel epigenetic target in breast cancer 51
null 3
Totale 22.549
Categoria #
all - tutte 58.578
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.578


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021203 0 0 0 0 0 0 0 0 0 0 0 203
2021/20221.055 107 94 124 110 87 91 59 43 53 43 101 143
2022/20231.440 157 403 162 156 104 183 11 78 102 6 59 19
2023/2024975 24 38 27 79 100 217 203 44 65 34 23 121
2024/20253.104 176 254 296 141 214 140 255 156 265 447 307 453
2025/202610.677 737 467 770 940 1.139 852 1.225 357 848 2.608 508 226
Totale 22.549